How big is the predictive biomarkers market?

The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is expected to reach USD 27.76 billion in 2025.

What is the predictive biomarkers market growth?

The global predictive biomarkers market is expected to witness a compound annual growth rate of 18.02% from 2025 to 2030 to reach USD 63.54 billion by 2030.

Which segment accounted for the largest predictive biomarkers market share?

The cancer segment dominated the market accounting for largest share of revenue with 37.19% in 2024, driven by the growing demand for early diagnosis, personalized treatment, and monitoring of treatment responses. The ability to identify specific genetic mutations, protein expressions, and other molecular alterations in cancer cells has transformed oncology, allowing for targeted therapies and improved patient outcomes

Who are the key players in predictive biomarkers market?

Some key players of this market include Thermo Fisher Scientific Inc., Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, Agilent Technologies, Inc., Illumina Inc., Merck KGaA, Bio-Techne, Siemens Healthineers AG, PerkinElmer, Myriad Genetics, Inc., Becton Dickinson, Danaher Corporation, Genomic Health, Inc., PacBio.

What are the factors driving the predictive biomarkers market?

The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments. Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates.